The advisors on MoonLake’s debt funding by Hercules Capital
Kellerhals Carrard advised Swiss clinical-stage biotechnology company MoonLake Immunotherapeutics on a debt funding deal with American venture lending specialist Hercules Capital, which was instead represented by Schellenberg Wittmer, acting as Swiss legal counsel.
The deal
The parties reached an agreement at $500 million in non-dilutive capital, with an initial $75 million drawn at closing.
Pursuant to the deal, additional tranches will become available upon achievement of certain pre-specified milestones in alignment with MoonLake’s strategy and funding needs.
The company
Headquartered in Zug, MoonLake Immunotherapeutics utilizes its Nanobody technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases.
The Kellerhals Carrard team
Partner Nicolas Mosimann (pictured above) led the Kellerhals Carrard startup & VC desk team on the matter, working alongside partner Marco Sibold (tax/corporate). Senior associate Kevin MacCabe, as well as associates Jon Oetiker and Kim Lindner, further contributed to the effort.
The Schellenberg Wittmer team
Philippe Borens (overall responsibility, pictured) led the Schellenberg Wittmer team on the transaction, working alongside Dominic Wälchli and Christoph Hügli (banking & finance) as well as Roland Wild and Tabea Bänteli (tax).
